No Data
No Data
Jefferies Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $12
BioCryst Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30
BioCryst Pharma Analyst Ratings
RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating
Express News | BioCryst Pharmaceuticals Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $15